Person: SÜMBÜL, BİLGE
3 results
Search Results
Now showing 1 - 3 of 3
Publication Metadata only Kronik Hemodiyaliz Hastalarında BNT162b2 ve CoronaVac’a Karşı Hümoral Yanıt: Çok Merkezli Prospektif Çalışma(2022-11-09) Mirioğlu Ş.; Kazancıoğlu R.; Cebeci E.; Eren N.; Sakacı T.; Alagöz S.; Tuğcu M.; Tuğlular Z. S.; Sümbül B.; Seyahi N.; et al.; MİRİOĞLU, ŞAFAK; KAZANCIOĞLU, RÜMEYZA; SÜMBÜL, BİLGEPublication Metadata only Thorax computed tomography findings and anti-SARS-CoV-2 immunoglobulin G levels in polymerase chain reaction-negative probable COVID-19 cases.(2022-11-25) Yurtsever I.; Karatoprak C.; Sumbul B.; Kiskac M.; Tunc M.; Zorlu M.; Ogun H.; Durdu B.; Toluk O.; Cakirca M.; YURTSEVER, İSMAİL; KARATOPRAK, CUMALİ; SÜMBÜL, BİLGE; KISKAÇ, MUHARREM; TUNÇ, MUHAMMED; ZORLU, MEHMET; OGUN, HAMZA; DURDU, BÜLENT; TOLUK, ÖZLEM; ÇAKIRCA, MUSTAFAOBJECTIVE: This study aimed to evaluate the SARS-CoV-2 immunoglobulin G (IgG) levels after 6 months of polymerase chain reaction (PCR) negativebut assumed to be COVID-19 positive cases to investigate the relationship between IgG levels and thoracic computed tomography (CT) findings.METHODS: This was a single-center study that included patients whose PCR test results were negative at least three times using nasopharyngealswabs but had clinical findings of COVID-19 and thoracic CT findings compatible with viral pneumonia. Six months after discharge, the IgG antibodieswere analyzed. The cutoff value for negative and positive serology was defined as <1.4 (index S/C) and ≥1.4 (index S/C), respectively. In addition, thepatients were categorized according to their thoracic CT findings as high (typical) and low (atypical). Also, the patients were grouped into classes as<5% lung involvement versus ≥5% lung involvement.RESULTS: The patients’ mean age was 49.78±12.96 years. PCR was negative, but patients with COVID-19 symptoms who had SARS-CoV-2 IgGpositive were 81.9% (n=95). The antibody titer and lung involvement ≥5% were statistically significantly higher in SARS-CoV-2 IgG positive cases(p<0.001 and p=0.021). Age and chest CT findings were the risk factors for lung involvement (OR=1.08, p<0.001 and OR=2.19, p=0.010, respectively).CONCLUSION: This study is valuable because increasing severity (≥5%) of lung involvement appears to be associated with high and persistent IgGantibody titers. In probable cases of COVID-19, even if the PCR test is negative, high IgG titers 6 months after discharge can predict the rate of lungparenchymal involvement.Publication Metadata only Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study(2024-01-01) Kiremitci S.; Kochan K.; SEVEN G.; Keskin E. B.; OKAY G.; AKKOYUNLU Y.; Koc M. M.; SÜMBÜL B.; ŞENTÜRK H.; KİREMİTÇİ, SERCAN; KOÇHAN, KORAY; SEVEN, GÜLSEREN; OKAY, GÜLAY; AKKOYUNLU, YASEMİN; SÜMBÜL, BİLGE; ŞENTÜRK, HAKANBackground/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accordance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAgnegative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36-276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of 2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-Treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-Threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated.